Main Article Content

Henna Salman
Sajid Razaq
Ayesha Qaisar
Shafaq Naz
Abdullah Khan
Jibran Umar Ayub Khan


celiac disease, ulcerative colitis


BACKGROUND: The treatment of irritable bowel syndrome has evolved over the last so many years ranging from simple conservative measures to medications such as rifaximin.1

OBJECTIVE: To compare the effectiveness of short course vs prolonged rifaximin for post infectious irritable bowel syndrome.

MATERIAL AND METHODS: This study was conducted in MMC General Hospital Peshawar after the scrutiny and proper approval of the proposal from the ethical review of the committee of the hospital. The patients of IBS diagnosed according to the modified Rome criteria were in the inclusion criteria and patients having diarrhea die to other causes such as celiac disease, crohns diseases, ulcerative colitis was excluded from the study. A sample size of 50 was taken and method used was non-probability convenient sampling. The responses of the participants were recorded through a validated questionnaire comparing the symptoms with short course and long course of Rifaximin. The data was analyzed by SPSS version 22. Descriptive statistics were applied and the frequencies and percentages were applied were applied for categorical data whereas Mean and SD were applied for quantitative data. Results: The mean age of the patients was 32 years with males affected more as compared to females .The mean differences for stool frequency of stools was 0.4800 ,standard error of mean 0.164 ,confidence ranging from 0.811 to 0.148 and a very statistically significant value of 0.005 .Similarly for stool consistency and  flatulence the mean differences 0.34 and 0.38 ,confidence interval ranging from 0.95 to 0.48 and 0.50 to 0.16 and highly statistically significant p values of 0.020 and 0.025 respectively.

CONCLUSION: So the long term rifaxmin therapy has better results for various symptoms of IBS.

Abstract 122 | PDF Downloads 68


1. Black CJ, Ford AC. Best management of irritable bowel syndrome. Frontline Gastroenterol. 2021;12(4):303–15.
2. Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M, et al. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United Eur Gastroenterol J. 2017;5(6):773–88.
3. Törnblom H, Goosey R, Wiseman G, Baker S, Emmanuel A. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys. United Eur Gastroenterol J. 2018;6(9):1417–27.
4. McGhie-Fraser B, Lucassen P, Ballering A, Abma I, Brouwers E, van Dulmen S, et al. Persistent somatic symptom related stigmatisation by healthcare professionals: A systematic review of questionnaire measurement instruments. J Psychosom Res [Internet]. 2023;166(October 2022):111161. Available from:
5. Nakov R, Snegarova V, Dimitrova-Yurukova D, Velikova T. Biomarkers in Irritable Bowel Syndrome: Biological Rationale and Diagnostic Value. Dig Dis. 2022;40(1):23–32.
6. Emmanuel A, Goosey RW, Wiseman G, Baker S, Törnblom H. Impact of symptom severity in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D): Results from two separate surveys of HCPs and patients with IBS-D. BMC Gastroenterol. 2020;20(1):1–10.
7. Algabr GA, Alotaibi TK, Alshaikh AM. Assessment of Knowledge, Attitude and Practice towards Irritable Bowel Syndrome and Risk Factors in Riyadh City, 2017. Egypt J Hosp Med. 2018;70(8):1377–80.
8. Vajravelu RK, Shapiro JM, Ni J, Thanawala SU, Lewis JD, El-Serag HB. Risk for Post-Colonoscopy Irritable Bowel Syndrome in Patients With and Without Antibiotic Exposure: A Retrospective Cohort Study. Clin Gastroenterol Hepatol [Internet]. 2022;20(6):e1305–22. Available from:
9. Austhof E, Schaefer K, Faulkner J, Bach L, Riddle M, Pogreba-Brown K. Knowledge and practices of primary care physicians or general practitioners treating post-infectious Irritable Bowel Syndrome. BMC Gastroenterol. 2020;20(1):1–6.
10. Chang C. Short-course therapy for diarrhea-predominant irritable bowel syndrome: Understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clin Exp Gastroenterol. 2018;11:335–45.
11. Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther [Internet]. 2020;37(1):83–96. Available from:
12. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. N Engl J Med. 2011;364(1):22–32.
13. Kim J, Park JH, Shin S. Effectiveness of simulation-based nursing eucation depending on fidelity: A meta analysis. BMC Med Educ [Internet]. 2016;16(1):1–8. Available from:

Most read articles by the same author(s)